



**World Health
Organization**

INN Working Document 25.615
11/03/2025

**Addendum* to
*"The use of stems in the selection of International
Nonproprietary Names (INN) for pharmaceutical
substances, 2024"***

ISBN 9-789240-099388

Programme on International Nonproprietary Names (INN)

***Health Products Policy and Standards (HPS)
Access to Medicines and Health Products (MHP)***

World Health Organization, Geneva

© World Health Organization 2025 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme.

This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Addendum* to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - ISBN 9-789240-099388

* This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" 2024.

-alkib	ALK (anaplastic lymphoma kinase) inhibitors dirozalkib (132), envonalkib (126), ficonalkib (128), neladalkib (130), iruplinalkib (126), zotizalkib (128) under (c) category: alectinib (108), brigatinib (113), ceritinib (109), crizotinib (103), ensartinib (115), nasartinib (115)
-ampator	α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators farampator (92), mibampator (103), osavampator (129), pesampator (126), tulrampator (116)
-cirnon	CC chemokine receptor (CCR) antagonists ilacirnon (123), lazucirnon (123), tivumecirnon (128), vercirnon (107), zelnecirnon (130)
-menin	menin interaction inhibitors balomenib (132), bleximenib (129), emilumenib (129), enzomenib (130), icovamenib (130), revumenib (126), ziftomenib (127)
-nosine	nucleoside analogues, antivirals or antineoplastics adenosine phosphate (14), alanosine (48), ateganosine (130), didanosine (64), fosdesdenosine sipalabenamide (130), inosine (42), lodenosine (78)
-protafib	protein tyrosine phosphatase (HPTP) inhibitors batoprotafib (127), ertiprotafib (87), migoprotafib (128), osunoprotafib (129), razuprotafib (116), tegeprotafib (129), vociprotafib (127)
-rogant	retinoic acid receptor-related orphan receptor gamma (RORγ) antagonists and inverse agonists bevurogant (125), cedirogant (123), izumerogant (128), retezorogant (126), vimirogant (120)
-stat -drostat	enzyme inhibitors aldosterone and cortisol synthesis inhibitors osilodrostat (110), baxdrostat (125), dexfadrostat (126), lorundrostat (127), vicadrostat (130)
-turev	under the advanced therapy scheme for: oncolytic viruses canerpaturev (117), gebasaxturev (126), lerapolturev (125), lino-serpaturev (131), suratadenoturev (123), tasadenoturev (117), teserpaturev (119) under (c) category: enadenotucirev (111)

-vatein	protein vaccine substances
-covatein	coronavirus carocovatein (128), enlicovatein (128), girocovatein (132), laricovatein (128), riticovatein (128), tibrecovatein (128) -alsecovatein (128), mivalsecovatein (131), upsalcovatein (129) -selvacovatein (128), damlecovatein (131) -sorimcovatein (128), pesorimcovatein (130), tisorimcovatein (130)
-vir	antivirals
-trelvir	antiviral 3CL protease inhibitors abimtrelovir (126), atilotrelovir (129), bofutrelovir (127), deunirmatrelovir (129), ensitrelovir (126), ibuzatrelovir (129), imocitrelovir (130), iscatrelovir (130), limnetrelovir (130), lufotrelovir (125), nirmatrelovir (126), olgotrelovir (129), pomotrelovir (127), ratutrelovir (132), secutrelovir (132), zevotrelovir (129)

Amendments were also made in the following stems' definitions:

-cianine

from *indocyanine fluorescence dye group*

to *cyanine dyes and their derivatives, diagnostic imaging agents*

-fylline (New)

from *N-methylated xanthine derivatives*

to *N-alkylated xanthine derivatives*

-ilide

from *class III antiarrhythmics, sematilide derivatives*

to *class III antiarrhythmics, ~~sematilide derivatives~~*

-kalim

from *potassium channel activators, antihypertensives.*

to *potassium channel activators, antihypertensives.*

-kinra (New)

from *interleukin receptor antagonists and interleukin antagonists*

to *interleukin receptor antagonists and interleukin inhibitors*

-(o)nidine

from *antihypertensives, clonidine derivatives*

to *α_2 adrenoreceptor agonists*

under *-rsen*

-dirsen

From *targeting muscular dystrophies*

To *splice-switching oligonucleotides, muscular dystrophies*

under -tant

-netant

from *neurokinin NK3 receptor antagonists*

to *neurokinin NK3 and dual NK3-NK1 receptor antagonists*

-tirom(e) (future use of final (e) is discouraged to avoid conflict with -terone stem)

from *antihyperlipidemic, thyromimetic derivatives*

to ~~*antihyperlipidemic*~~, *thyromimetic derivatives*

Amendments were also made in the stem's infix:

-gromab (under -mab)

from -*gros*mab

for the designation of INN for monoclonal antibodies targeting skeletal muscle mass related growth factors and receptors

-ki- (under -mab)

for the designation of INN for monoclonal antibodies targeting interleukins,

to cytokine and cytokine receptors

Please note that a new naming scheme for monoclonal antibodies was adopted at the 73rd

INN Consultation. The document can be retrieved here after and from our webpages at:

[https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-\(inn\)/new_mab_-nomenclature-_2021.pdf?sfvrsn=207e78cb_12&download=true](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/new_mab_-nomenclature-_2021.pdf?sfvrsn=207e78cb_12&download=true)